NPS
Pharmaceuticals, Inc. is a biopharmaceutical company that develops and
commercializes innovative therapies for patients with rare diseases.
The company's lead product, Gattex (teduglutide), is an injectable
drug that is used to treat short bowel syndrome (SBS), a rare
condition that can cause malnutrition and dehydration due to the
inability to absorb nutrients from food. Gattex is the first and only
FDA-approved treatment for SBS.
NPS Pharmaceuticals also has
other products in development for the treatment of rare diseases,
including Natpara (recombinant human parathyroid hormone), which has
been approved by the FDA for the treatment of hypoparathyroidism, a
rare disorder that can cause low levels of calcium in the blood.
The company was founded in 1986 and is headquartered in
Bedminster, New Jersey. In 2015, NPS Pharmaceuticals was acquired by
Shire plc, a global biopharmaceutical company, for $5
NPS
Pharmaceuticals, Inc. is a biopharmaceutical company that develops and
commercializes innovative therapies for patients with rare diseases.
The company's lead product, Gattex (teduglutide), is an injectable
drug that is used to treat short bowel syndrome (SBS), a rare
condition that can cause malnutrition and dehydration due to the
inability to absorb nutrients from food. Gattex is the first and only
FDA-approved treatment for SBS.